Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 103

The DOI matches its Crossref record.

Role of Human Albumin in the Management of Complications of Liver Cirrhosis

Bernardi, Mauro, Ricci, Carmen S., Zaccherini, Giacomo·2014·Journal of Clinical and Experimental Hepatology
DOI 10.1016/j.jceh.2014.08.007
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jceh.2014.08.007

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 47

  1. He, 1992, Atomic structure and chemistry of human serum albumin, Nature, 358, 209, 10.1038/358209a0 · DOI · Paper page
  2. Carter, 1989, Three-dimensional structure of human serum albumin, Science, 244, 1195, 10.1126/science.2727704 · DOI · Paper page
  3. Kragh-Hansen, 1990, Structure and ligand binding properties of human serum albumin, Dan Med Bull, 37, 57
  4. Quinlan, 2005, Albumin: biochemical properties and therapeutic potential, Hepatology, 41, 1211, 10.1002/hep.20720 · DOI · Paper page
  5. Chen, 2012, Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway, Cardiovasc Res, 93, 141, 10.1093/cvr/cvr279 · DOI
  6. Henricksen, 2001, Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis, J Hepatol, 34, 53, 10.1016/S0168-8278(00)00009-X · DOI
  7. Garcia-Martinez, 2013, Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications, Hepatology, 58, 1836, 10.1002/hep.26338 · DOI · Paper page
  8. Oettl, 2007, Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties, Br J Pharmacol, 151, 580, 10.1038/sj.bjp.0707251 · DOI · Paper page
  9. Bruschi, 2013, Oxidized albumin. The long way of a protein of uncertain function, Biochim Biophys Acta, 1830, 5473, 10.1016/j.bbagen.2013.04.017 · DOI
  10. Bernardi, 2005, Disturbances of acid-base balance in cirrhosis: a neglected issue warranting further insights, Liver Int, 2, 463, 10.1111/j.1478-3231.2005.01115.x · DOI
  11. Oettl, 2008, Oxidative damage of albumin in advanced liver disease, Biochim Biophys Acta, 1782, 469, 10.1016/j.bbadis.2008.04.002 · DOI
  12. Jalan, 2009, Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality, Hepatology, 50, 555, 10.1002/hep.22913 · DOI
  13. Domenicali, 2014, Post-transcriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis, Hepatology, 10.1002/hep.27322 · DOI
  14. Henriksen, 1980, Intraperitoneal pressure: ascitic fluid and splanchnic vascular pressures, and their role in prevention and formation of ascites, Scand J Clin Lab Invest, 40, 493, 10.3109/00365518009091956 · DOI
  15. Arroyo, 2011, Pathophysiological basis of albumin use in cirrhosis, Ann Hepatol, 10, S6, 10.1016/S1665-2681(19)31600-X · DOI
  16. Bernardi, 2012, Human albumin in the management of complications of liver cirrhosis, Crit Care, 16, 211, 10.1186/cc11218 · DOI · Paper page
  17. Ruiz-del-Arbol, 1997, Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis, Gastroenterology, 113, 579, 10.1053/gast.1997.v113.pm9247479 · DOI · Paper page
  18. Ginès, 1996, Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis, Gastroenterology, 111, 1002, 10.1016/S0016-5085(96)70068-9 · DOI · Paper page
  19. Ginès, 1988, Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis, Gastroenterology, 94, 1493, 10.1016/0016-5085(88)90691-9 · DOI · Paper page
  20. Sola-Vera, 2003, Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites, Hepatology, 37, 1147, 10.1053/jhep.2003.50169 · DOI
  21. Moreau, 2006, Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial, Liver Int, 26, 46, 10.1111/j.1478-3231.2005.01188.x · DOI
  22. Bernardi, 2012, Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials, Hepatology, 55, 1172, 10.1002/hep.24786 · DOI · Paper page
  23. Rimola, 2000, Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club, J Hepatol, 32, 142, 10.1016/S0168-8278(00)80201-9 · DOI · Paper page
  24. European Association for the Study of the Liver, 2010, EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis, J Hepatol, 53, 397, 10.1016/j.jhep.2010.05.004 · DOI · Paper page
  25. Fernández, 2012, Management of bacterial infections in cirrhosis, J Hepatol, 56, S1, 10.1016/S0168-8278(12)60002-6 · DOI · Paper page
  26. Salerno, 2007, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis, Gut, 56, 1310
  27. Salerno, 2014, Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis, Hepatology, 59, 1239, 10.1002/hep.27015 · DOI
  28. Gluud, 2010, Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome, Hepatology, 51, 576, 10.1002/hep.23286 · DOI · Paper page
  29. Martín-Llahí, 2008, Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study, Gastroenterology, 134, 1352, 10.1053/j.gastro.2008.02.024 · DOI · Paper page
  30. Sanyal, 2008, A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome, Gastroenterology, 134, 1360, 10.1053/j.gastro.2008.02.014 · DOI · Paper page
  31. Ortega, 2002, Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study, Hepatology, 36, 941, 10.1053/jhep.2002.35819 · DOI
  32. Terra, 2005, Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score, Gastroenterology, 129, 1944, 10.1053/j.gastro.2005.09.024 · DOI · Paper page
  33. Fasolato, 2007, Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features, Hepatology, 45, 223, 10.1002/hep.21443 · DOI · Paper page
  34. Guevara, 2012, Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study, J Hepatol, 57, 759, 10.1016/j.jhep.2012.06.013 · DOI
  35. Khungar, 2012, Hepatic encephalopathy, Clin Liver Dis, 16, 301, 10.1016/j.cld.2012.03.009 · DOI
  36. Bajaj, 2011, The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers, Am J Gastroenterol, 106, 1646, 10.1038/ajg.2011.157 · DOI · Paper page
  37. García-Martínez, 2011, Acute-on-chronic liver failure: the brain, Curr Opin Crit Care, 17, 177
  38. Als-Nielsen, 2004, Nonabsorbable disaccharides for hepatic encephalopathy, Cochrane Database Syst Rev, CD003044
  39. Bass, 2010, Rifaximin treatment in hepatic encephalopathy, N Eng J Med, 362, 1071, 10.1056/NEJMoa0907893 · DOI · Paper page
  40. Jalan, 2004, Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid, Clin Sci, 106, 467, 10.1042/CS20030357 · DOI
  41. Simón-Talero, 2013, Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study, J Hepatol, 59, 1184, 10.1016/j.jhep.2013.07.020 · DOI
  42. Gentilini, 1999, Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial, J Hepatol, 30, 639, 10.1016/S0168-8278(99)80194-9 · DOI
  43. Romanelli, 2006, Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial, World J Gastroenterol, 12, 1403, 10.3748/wjg.v12.i9.1403 · DOI
  44. Bortoluzzi, 2013, Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms, Hepatology, 57, 266, 10.1002/hep.26021 · DOI
  45. Bañares, 2013, Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial, Hepatology, 57, 1153, 10.1002/hep.26185 · DOI · Paper page
  46. Dethloff, 2008, Effect of prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study, World J Gastroenterol, 14, 2065, 10.3748/wjg.14.2065 · DOI
  47. Mirici-Cappa, 2011, How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure, World J Gastroenterol, 17, 3479, 10.3748/wjg.v17.i30.3479 · DOI

Cited by

Metadata

Authors
Bernardi, M., Ricci, C. S., & Zaccherini, G.
Venue
Journal of Clinical and Experimental Hepatology
Publisher
Elsevier BV
Published
2014-12
Volume
4
Issue
4
Pages
302-311
ISSN
0973-6883
DOI
10.1016/j.jceh.2014.08.007
Cited by
103
References
0
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.